메뉴 건너뛰기




Volumn 79, Issue 4, 2012, Pages 296-297

Door-to-needle times in acute ischemic stroke: How low can we go?

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

EID: 84866075957     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31825d602e     Document Type: Editorial
Times cited : (9)

References (9)
  • 1
    • 77952112006 scopus 로고    scopus 로고
    • Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    • Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
    • (2010) Lancet , vol.375 , pp. 1695-1703
    • Lees, K.R.1    Bluhmki, E.2    Von Kummer, R.3
  • 2
  • 3
    • 79952073474 scopus 로고    scopus 로고
    • Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes
    • Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011;123:750 -758.
    • (2011) Circulation , vol.123 , pp. 750-758
    • Fonarow, G.C.1    Smith, E.E.2    Saver, J.L.3
  • 4
    • 77955665657 scopus 로고    scopus 로고
    • Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR
    • Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-874.
    • (2010) Lancet Neurol , vol.9 , pp. 866-874
    • Ahmed, N.1    Wahlgren, N.2    Grond, M.3
  • 6
    • 79959981013 scopus 로고    scopus 로고
    • Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years
    • Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
    • (2011) Stroke , vol.42 , pp. 1952-1955
    • Adeoye, O.1    Hornung, R.2    Khatri, P.3    Kleindorfer, D.4
  • 7
    • 80053298469 scopus 로고    scopus 로고
    • Improving doorto-needle times in acute ischemic stroke: The design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative
    • Fonarow GC, Smith EE, Saver JL, et al. Improving doorto-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: stroke initiative. Stroke 2011; 42:2983-2989.
    • (2011) Stroke , vol.42 , pp. 2983-2989
    • Fonarow, G.C.1    Smith, E.E.2    Saver, J.L.3
  • 8
    • 8644230974 scopus 로고    scopus 로고
    • Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke
    • Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170 -2178.
    • (2004) N Engl J Med , vol.351 , pp. 2170-2178
    • Alexandrov, A.V.1    Molina, C.A.2    Grotta, J.C.3
  • 9
    • 66849141260 scopus 로고    scopus 로고
    • After European Cooperative Acute Stroke Study 3: Mission accomplished?
    • von Kummer R. After European Cooperative Acute Stroke Study 3: mission accomplished? Stroke 2009;40:2268-2270.
    • (2009) Stroke , vol.40 , pp. 2268-2270
    • Von Kummer, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.